Exabis Library
Welcome to the e-CCO Library!
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
Wednesday, 27 February 2019, 4:37 PM by ECCO Administrator
DOP63: Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP63: The Toronto IBD global endoscopic reporting (TIGER) score is well correlated with fecal calprotectin and IBD Disk in Ulcerative Colitis patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP63: Time Trends of Environmental and Socio-economical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis revisited.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP64: Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP64: Pathogenic RIPK1 Mutations Cause Infantile-onset IBD with Inflammatory and Fistulizing Features
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP64: Utilising genomics to predict outcomes and delineate novel subgroups in inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP65: Development and validation of the TUMMY-UC, a patient-reported outcome in pediatric Ulcerative Colitis: A multicenter prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP65: Dietary therapy with the Crohn’s Disease exclusion diet induces sustained clinical and endoscopic remission in adults with Mild to Moderate Crohn's Disease: Results from the CDED-AD trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP65: T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn's Disease patients with perianal fistulizing disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP66: Disease course of Ulcerative proctitis in children: A population based study on behalf of the SIGENP IBD Group
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP66: Ileal resections from fibrotic-CD patients present microbiota dysbiosis, altered metabolomic profiles and metabolite-sensing GPCRs expression
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP66: The effect of exclusive enteral nutrition on circulating inflammatory protein levels in paediatric patients with Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM